Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 30 mg - morphine sulfate tablets contain morphine, an opioid analgesic, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. morphine sulfate is contraindicated in patients with known hypersensitivity to morphine, morphine salts, or any components of the product. morphine sulfate is contraindicated in patients with respiratory depression in the absence of resuscitative equipment. morphine sulfate is contraindicated in patients with acute or severe bronchial asthma or hypercarbia. morphine sulfate is contraindicated in any patient who has or is suspected of having paralytic ileus. animal reproduction studies have not been conducted with morphine sulfate. it is also not known whether morphine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. only give morphine sulfate to a pregnant woman if clearly needed. in humans, the frequency of congenital anomalies has been reported to be no greater than expecte

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

physicians total care, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate tablets contain morphine, an opioid analgesic, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. morphine sulfate is contraindicated in patients with known hypersensitivity to morphine, morphine salts, or any components of the product. morphine sulfate is contraindicated in patients with respiratory depression in the absence of resuscitative equipment. morphine sulfate is contraindicated in patients with acute or severe bronchial asthma or hypercarbia. morphine sulfate is contraindicated in any patient who has or is suspected of having paralytic ileus. animal reproduction studies have not been conducted with morphine sulfate. it is also not known whether morphine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. only give morphine sulfate to a pregnant woman if clearly needed. in humans, the frequency of congenital anomalies has been reported to be no greater than expecte

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 30 mg - capsule, modified release - excipient ingredients: macrogol 6000; gelatin; purified talc; titanium dioxide; magnesium stearate; hydrogenated vegetable oil; sodium lauryl sulfate; indigo carmine; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 60 mg - capsule, modified release - excipient ingredients: iron oxide red; sodium lauryl sulfate; indigo carmine; magnesium stearate; titanium dioxide; purified talc; macrogol 6000; iron oxide yellow; gelatin; hydrogenated vegetable oil; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 90 mg - capsule, modified release - excipient ingredients: purified talc; iron oxide red; titanium dioxide; magnesium stearate; sodium lauryl sulfate; iron oxide black; macrogol 6000; erythrosine; hydrogenated vegetable oil; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 120 mg - capsule, modified release - excipient ingredients: iron oxide yellow; sodium lauryl sulfate; purified talc; titanium dioxide; magnesium stearate; gelatin; indigo carmine; iron oxide black; macrogol 6000; hydrogenated vegetable oil; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

novel laboratories, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non- opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - morphine sulfate extended-release tablets is not indicated as an as-needed (prn) analgesic. morphine sulfate extended-release tablets are contraindicated in patients with: - significant respiratory depression [see warnings and pr

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

paddock laboratories, llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 100 mg in 5 ml - morphine sulfate oral solution is indicated for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. morphine sulfate oral solution 100 mg per 5 ml (20 mg/ml) is indicated for the relief of acute and chronic pain in opioid-tolerant patients. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2) ], reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: morphine sulfate oral solution is contraindicated in patients with: risk summary prolonged use of opioid analgesics during pregnancy can cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.5) ]. there are no available data with morphine sulfate oral solution in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. published s

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 60 mg - morphine sulfate extended-release tablets are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. morphine sulfate extended-release tablets are not intended for use as a prn analgesic. the morphine sulfate extended-release tablets 100 mg and 200 mg strengths are high dose, extended-release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only. morphine sulfate extended-release tablets are not indicated for pain in the immediate postoperative period (the first 12 to 24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. morphine sulfate extended-release tablets are not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time. morphine sulfate extended-release ta

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use morphine sulfate extended-release tablets are contraindicated in patients with: risk summary prolonged use of opioid analgesics during pregnancy may cause neonatal withdrawal syndrome [see warnings and precautions (5.3)] . there are no available data with morphine sulfate extended-release tablets in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. published studies with morphine use during pregnancy have not reported a clear association with morphine and major birth defects [see human data]. in published animal reproduction studies, morphine administered subcutaneously during the early gestational period produced neural tube defects (i.e., exencephaly and cranioschisis) at 5 and 16 times the human daily dose of 60 mg based on body surf